Neuland Laboratories Limited has informed the Exchange regarding Appointment of Mr Ravi Shankar Gopinath as Non- Executive Independent Director of the company w.e.f. August 01, 2025.
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Neuland Laboratories reported Q1 FY26 (quarter ended June 30, 2025) standalone revenue of ₹29,275 lakhs and profit after tax of ₹1,371 lakhs, compared to ₹43,960 lakhs and ₹9,834 lakhs in Q1 FY25 (which included a ₹2,063 lakh exceptional gain from transfer of an investment property). Consolidated revenue was ₹29,275 lakhs with PAT of ₹1,390 lakhs and EPS of ₹10.83. Total expenses were largely flat year-on-year. The board also approved the appointment of Dr. Ravi Shankar Gopinath (aged 60) as an Additional Independent Director for a five-year term effective August 1, 2025, subject to shareholder approval. Dr. Gopinath holds a PhD in Chemical Engineering from Rensselaer Polytechnic Institute and brings over 30 years of global experience in strategy, M&A, and scaling businesses. Limited review reports by statutory auditors MSKA & Associates issued an unmodified conclusion.
The steep year-on-year profit decline is largely explained by the absence of last year's one-time property transfer gain; underlying operations appear broadly stable. The new independent director adds deep global pharma and strategy experience to the board, which is mildly positive for governance and long-term direction.